Form 4: Edwards Lifesciences CEO Bernard Zovighian Reports Stock Transactions

CEO Bernard Zovighian reports exercising stock options and selling shares of Edwards Lifesciences common stock under a pre-arranged trading plan.

Summary

• Bernard J. Zovighian, CEO of Edwards Lifesciences, reported transactions involving the company's common stock on March 10, 2025.
• He exercised employee stock options to acquire 7,463 shares at a price of $45.2767 per share.
• He then sold 6,164 shares at a weighted average price of $69.5081 per share, with individual trades ranging from $69.41 to $69.64.
• Zovighian also reported gifting 1,299 shares.
• Following these transactions, he directly owns 59,082.9006 shares and indirectly owns 10,436 shares through a trust and 3,495.2761 shares through a 401(k) plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are part of a pre-planned trading strategy, and there's no indication of unusual activity or concern.

Positives

• The transactions were conducted under a pre-arranged 10b5-1 trading plan, suggesting they were planned and not based on immediate insider information.

Negatives

• The sale of shares by the CEO could be perceived negatively by some investors, although it is part of a pre-planned strategy.

Risks

• While the transactions are part of a pre-arranged plan, significant sales by executives can sometimes create short-term price volatility.

Future Outlook

The document does not contain specific forward-looking statements, but it indicates ongoing transactions under a pre-arranged trading plan.

Industry Context

Insider transactions are common in publicly traded companies, and the reporting of these transactions is a standard regulatory requirement. The use of a 10b5-1 trading plan is a common practice to avoid accusations of insider trading.

Comparison to Industry Standards

• Comparing the CEO's transactions to those of executives at similar medical device companies like Medtronic or Abbott would provide context on whether these actions are typical.
• Reviewing the frequency and size of insider transactions at these companies can help determine if Zovighian's actions are within the norm.
• Benchmarking against industry averages for executive compensation and stock ownership can also offer valuable insights.

Stakeholder Impact

• The transactions could have a minor impact on shareholders due to the potential for short-term price fluctuations.
• Employees may be indirectly affected by any changes in stock price, particularly those holding company stock or options.

Key Dates